Achilles Therapeutics PLC

<!-- Name:DistributionId Value:8835388 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy - - Updated interim Phase I/II results show encouraging safety and…

- Patient enrolled at the Moffitt Cancer Center, FL where Dr. Benjamin Creelan is the Principal Investigator - - CHIRON trial is enrolling up to 40 patients with advanced unresectable or metastatic non-small cell lung cancer at clinical…